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Abstract
Background: Techniques for detecting circulating tumor cells in the peripheral blood of patients
with head and neck cancers may identify individuals likely to benefit from early systemic treatment.
Methods: Reconstruction experiments were used to optimise immunomagnetic enrichment and
RT-PCR detection of circulating tumor cells using four markers (ELF3, CK19, EGFR and EphB4). This
method was then tested in a pilot study using samples from 16 patients with advanced head and
neck carcinomas.
Results: Seven patients were positive for circulating tumour cells both prior to and after surgery,
4 patients were positive prior to but not after surgery, 3 patients were positive after but not prior
to surgery and 2 patients were negative. Two patients tested positive for circulating cells but there
was no other evidence of tumor spread. Given this patient cohort had mostly advanced disease, as
expected the detection of circulating tumour cells was not associated with significant differences in
overall or disease free survival.
Conclusion: For the first time, we show that almost all patients with advanced head and neck
cancers have circulating cells at the time of surgery. The clinical application of techniques for
detection of spreading disease, such as the immunomagnetic enrichment RT-PCR analysis used in
this study, should be explored further.
Background
Head and neck cancers include several histologically dis-
tinct cancers that originate in the upper airways. Advances
in surgery and radiotherapy over the past few decades
have resulted in improved loco regional control however
this has not translated to an improved overall survival in
all studies. This is due in part to the development of sec-
ond primary tumours and distant metastases, which occur
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tems frequently fail to predict tumour biology and out-
come highlighting the need for more sensitive and specific
methods for the detection of spreading tumour cells.
Hematogenous spread of tumor cells from a primary
tumor can be considered as a crucial step in the metastasis
cascade that can lead eventually to the formation of clini-
cally manifest metastases [2]. Although it is likely that
only a small percentage of the tumour cells that are shed
into the peripheral blood will successfully lodge and con-
tinue to proliferate in distant sites, the presence of these
cells within the circulation indicates that the disease has
progressed to a stage where metastasis is possible. Indeed,
the clinical relevance of the use of methods for the detec-
tion of tumour cells disseminated via peripheral blood
has already been demonstrated by several studies of sam-
ples from patients with solid epithelial cancers including
breast, prostate and colorectal [3,4]. The use of methods
for the detection of haematogenous spread of tumour
cells from head and neck squamous cell carcinomas
(HNSCCs) may also prove to be of clinical relevance for
patient prognosis, staging and monitoring of therapy.
Successful detection of rare tumour cells in blood samples
that may contain up to 10^7 nucleated haematopoietic
cells can be achieved by combining pre-analytical enrich-
ment with molecular detection of enriched cells using
reverse transcriptase-polymerase chain reaction (RT-PCR)
assays [5-7]. The sensitive and specific detection of these
enriched cells would benefit from the identification of
markers that have high levels of tumour-specific expres-
sion, but to date no such tumour-specific transcripts have
been identified for any solid epithelial cancer [4]. For this
reason, and due to the heterogeneity of marker gene
expression profiles in most solid tumours including those
of head and neck origins, a panel of markers that show
increased expression in tumour cells compared to normal
epithelial cells is recommended [3,8,9].
In this study, an assay for the detection of circulating
tumor cells (CTCs) originating from head and neck squa-
mous cell carcinomas was developed, using reconstruc-
tion experiments combining pre-analytical enrichment of
HNSCC cell lines inoculated into peripheral blood from
normal individuals via BerEP4-conjugated immunomag-
netic beads (immunobeads) with subsequent RT-PCR
detection of a panel of four markers (Immunobead RT-
PCR) [10]. The BerEP4 antibody recognises the EpCam
protein expressed on the surface of epithelial cells. The
markers used for RT-PCR included epidermal growth fac-
tor receptor (EGFR), the Eph receptor tyrosine kinase B4
(EphB4), cytokeratin 19 (CK19) and the Ets transcription
factor, Elf3/ESX and were chosen based on reported
expression in epithelial cancers including those originat-
ing from head and neck origins. Previous studies per-
formed in our laboratory have reported the use of these
markers for the identification of circulating breast cancer
cells [10,11]. Optimisation experiments using peripheral
blood samples from normal individuals showed that
none of these four markers can be detected in normal
mononuclear cells under the described conditions and
that these markers are therefore specific for the detection
of circulating epithelial cells [10-12].
Activation of EGFR signalling cascades are associated with
cell proliferation, metastasis, angiogenesis and inhibition
of apoptosis and EGFR has been reported as over-
expressed in 80-100% of HNSCC where it is associated
with resistance to treatment and poor clinical outcome
[13-15]. EphB4 is similarly over-expressed in head and
neck cancers (100% of 37 cases examined) and knockout
studies using siRNA and antisense both in vitro and
importantly, in vivo, have demonstrated that EphB4 has
an essential role in many processes that contribute to can-
cer cell survival and spread [16,17]. Cytokeratins such as
CK19 are almost exclusively expressed in epithelial tissues
and are commonly used as markers for the detection of
disseminated tumour cells of epithelial origin [18-20].
Expression of CK19 in particular increases in hyperplastic
lesions and continues to be expressed in dysplastic and
malignant lesions. More recently, Tao et al (2006) report
a real-time RT-PCR assay analysing CK19 mRNA level as a
sensitive and reliable method for the detection of carcino-
matous HNSCC cells in lymph nodes and increased CK19
expression has been reported to be associated with local
failure and distant metastasis in HNSCC [21,22]. Elf3, or
epithelial specific with serine box (ESX), is a member of
the Ets family of transcription factors and its expression is
limited to cells of epithelial origin and often up-regulated
in cancer cells [23].
The immunobead RT-PCR assay was then used in a pilot
study to screen peripheral blood samples taken from 16
patients with advanced HNSCC both before, and immedi-
ately after, surgery for the presence of marker-positive
CTCs. The clinical relevance of the detection of CTCs in
late stage HNSCC is discussed.
Methods
Patient Samples
Sixteen patients (14 males and 2 females) with newly
diagnosed advanced head and neck squamous cell carci-
nomas were enrolled prospectively into the study between
February and September of 2005 and were treated with
curative intent with primary surgery (Table 1). All patients
underwent CT examination of the head, neck, chest and
abdomen and were staged following a formal panendos-Page 2 of 15
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P# Cancer Site T N M Stage P V E Margin Diff
1 Rt Hypopharynx 1 2b 0 4a n n n involved poor
2 Lt Tongue Base 2 1 0 3 n Y n involved mod
3 FOM 4 0 0 4a Y n x x poor
4 RT Supraglottis 2 2b 0 4a n n Y clear poor
5 Rt Tongue Base 1 2b 0 4a n n Y involved mod
6 Rt Tongue Base 2 1 0 3 n Y n clear mod
7 Lt Hypopharynx 4 2c 0 4a n n Y 5 mm poor
8 Glottic 4 0 0 4a x n x clear mod
9 Rt Lat Tongue 1 0 0 1 Y n x 10 mm well
10 Lt Tonsil 3 2b 0 4a n n Y involved poor
11 Rt Tonsil 2 2b 0 4a n n Y clear mod
12 Glottic 3 0 0 3 x n x 15 mm mod
13 Glottic 3 0 0 3 n n x 0 mm mod
14 Transglottic 4 0 0 4a x Y x 1 mm Mod
15 Rt Lat Tongue 3 1 0 3 n n Y 3 mm poor
16 Rt Lat Tongue 3 0 0 3 n n x 0.6 mm well
P# Recurrence Radiation Chemo Outcome Before After
1 Distant Y - 66 Gy in 32 n Alive - metastatic disease neg POS
2 Local (tonsil) Y - 64 Gy in 31 n Died - disease POS neg
3 Local (tongue) Y - 64 Gy in 32 n Died - disease POS neg
4 Local (Node) Y - 66 Gy in 32 n Died - disease POS neg
5 Local Y - 66 Gy in 33 n Died - metastatic disease POS neg
6 n n n Alive - Disease Free POS POS
7 Distant Y - 66 Gy in 32 n died - metastatic disease POS POS
8 n Y - 66 Gy in 33 n Alive - Disease Free POS POS
9 Distant Y - 66 Gy in 34 n died - metastatic disease POS POS
10 Distant Y - 66 Gy in 35 Y died - metastatic disease neg POS
11 n Y - 66 Gy in 36 Y Alive - Disease Free POS POSPage 3 of 15
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(RT) or chemotherapy was made in a multidisciplinary
setting following surgery in conjunction with the histol-
ogy results and the patient's wishes. Patients who had pre-
viously been treated for HNSCC or who were to receive RT
or chemotherapy prior to surgery were excluded. Clinical
data including date of birth, sex, tumour subsite, tumour
stage, post-operative RT or chemotherapy, disease recur-
rence and survival were recorded. For the purpose of the
analysis tumours were staged based on the pathological
resection specimens according to the AJCC/UICC TNM
tumour classification [24]. The median age was 59 years
(range 44-83 years) with 1 patient diagnosed as stage 1, 6
patients diagnosed as stage 3 and 9 patients diagnosed as
stage 4a. Outcome data included all events occurring
immediately after surgery. Peripheral blood was collected
into dipotassium EDTA tubes from an arterial line at the
commencement and end of surgery. For the reconstruc-
tion experiments venous peripheral blood samples were
collected from normal individuals, also into dipotassium
EDTA tubes. All samples were processed within 2 h of col-
lection. Informed consent was obtained from all patients
and normal individuals and the research protocol was
approved by the Royal Adelaide Ethics Committee.
Cell culture
The four HNSCC cell lines used in this study were SCC-9,
SCC-25, Detroit 562 and FaDu and were all purchased
from the American Type Culture Collection (ATCC, Rock-
ville, MD). Cells were cultured in Dulbecco's Modified
Eagle Medium (Invitrogen, Carlsbad, CA), pH 7.4, in 75
cm2 vented tissue culture flasks at 37°C in a 5% CO2 envi-
ronment. The medium was supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin, 160 μg/ml L-
glutamine and 10% heat-inactivated foetal bovine serum
(JRH Biosciences, Lenexa, KS). Cells were collected at
>90% confluency by trypsin digestion and centrifugation
for 5 min at 1000 rpm, resuspended in phosphate buff-
ered saline (PBS) and counted using a haemocytometer.
Comparison of attachment of BerEP4 and EMA labelled 
immunobeads to tumour cells in vitro
Dynabeads M-450 covalently coated with sheep anti-
mouse IgG (Invitrogen) were labelled with 2 μg of either
the BerEP4 antibody (Dako, Denmark A/S) or an EMA
antibody (Dako) per mg beads according to the manufac-
turer's recommendations. In separate experiments, 1 × 104
cells of all four HNSCC cell lines were resuspended in 1.5
ml of fresh culture medium in 2 ml eppendorf tubes. To
this, 5 μl of labeled beads (approximately 2 × 105 in total)
were added and the samples placed on a low speed rotat-
ing wheel at 4°C for 1 h. Cells and beads were collected
by centrifugation at 1000 rpm for 5 min and the pelleted
cells resuspended in 100 μl PBS. A 50 μl sample was
placed on a microscope slide and visualised using a Nikon
Eclipse E800 light microscope to compare attachment of
beads to cells. Cells within several fields of view were
counted, the number with beads attached or not recorded,
and the number of beads actually attached to cells also
counted and recorded. An image of a representative field
of view was also taken.
RT-PCR analysis of marker gene expression in selected 
HNSCC cell lines
Total RNA was isolated directly from monolayers of
HNSCC cell lines FaDu and Detroit 562 using Trizol™ and
the manufacturer's recommendations (Invitrogen). A 2 μg
sample was then reverse transcribed at 37°C using 3 μl
pD(N)6 primers (Invitrogen), 200 μM each deoxyribonu-
cleotide triphosphate (dNTP) (Pharmacia, Uppsala, Swe-
den) and 200 U MMLV reverse transcriptase (Invitrogen)
in a reaction volume of 30 μl. Primers specific to the cho-
sen marker genes were as described in Raynor et al, 2002
(Table 2) [10]. The primers used to amplify CK19 have
been validated by both Eaton et al (1997) [5] and Hard-
ingham et al (2000) [25] and will not amplify either pseu-
dogenes or genomic DNA at the 68°C annealing
temperature used here. Primer pairs were used in PCR
reactions performed in a Perkin Elmer PTC100 thermocy-
12 n n n died - other neg neg
13 Local Y - 64 Gy in 31 Y Alive - Disease Free POS POS
14 Local Y - 64 Gy in 31 n died - metastatic disease neg neg
15 Local n n died - metastatic disease POS POS
16 n n n Alive - Disease Free neg POS
P# denotes patient number. Information includes - Site of original cancer (cancer site); tumour size (T); nodal status (N); evidence of metastasis (M); 
evidence of perineural invasion (P); evidence of vascular invasion (V); evidence of extracapsular invasion (E); whether the margin was involved with 
tumour after surgery or clear; differentiation of the tumour (Diff); Site of recurrence (Recurrence); whether (Y), or not (n), radiation was given 
post-surgery (Radiation) including dosage - Grays (Gy) in fractions; whether (Y), or not (n), chemotherapy was given (Chemo); the outcome at last 
follow-up (Outcome); and whether the patients were positive (POS) or negative (neg), before and after surgery for at least 2 of the RT-PCR 
markers. Y denotes yes, n denotes no, x denotes unknown.
Table 1: Disease characteristics of the 16 patients with head and neck cancers included in this study. (Continued)Page 4 of 15
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1.5 mM MgCl2, 200 μM each dNTP, 50 ng of each forward
and reverse primer, and 0.5 units of Hot Star Taq polymer-
ase in 1× PCR buffer (Qiagen). Cycling conditions
included an initial denaturation at 95°C for 15 min, fol-
lowed by 40 cycles of 96°C for 30 sec, 68°C for 1 min,
and 72°C for 1 min, with a final extension of 72°C for 7
min. Amplification products were visualised by ethidium
bromide staining following separation by electrophoresis
through 1.5% agarose gels.
Reconstruction "spiking" experiments to determine limit 
of detection of HNSCC cells in blood samples using 
immunobead RT-PCR
HNSCC cell lines Detroit and FaDu were diluted in PBS
and counted and seeded into 10 ml peripheral venous
blood samples collected from normal healthy individuals
at final concentrations of 10, 50, 100 and 500 cells per 10
ml in triplicate. A recent study by Balasubramanian et al
(2009) determined that the number of circulating tumour
cells in head and neck patients ranged from 0 to 214 per
ml therefore the range we have chosen for these recon-
struction experiments will be suitable to determine the
lower limit of detection of HNSCC [26].
A 10 μl aliquot of CELLection Epithelial Enrich Dyna-
beads (Dynal, Invitrogen) was added to each sample
before these were placed on a low speed rotating wheel at
4°C for 1 h. Enrichment of the cells to which beads had
attached in this time was achieved by juxtaposition to an
MPC magnet (Dynal, Invitrogen) for 5 min. The medium
and cells to which beads had not attached were removed
while the tube was in the magnetic holder and replaced
with phosphate buffered saline (PBS). The samples were
removed from the magnet and resuspended fully in the
PBS wash before a second magnetic collection. Samples
were washed in this manner a total of three times to
ensure the collection only of cells to which beads had
attached. After the final PBS wash, cells were collected to
the bottom of the tube and the PBS removed before the
addition of 9.5 μl of a cell lysis solution containing 0.3%
v/v Nonidet P-40 detergent (Sigma), 500 ng pD(N)6 prim-
ers (Invitrogen), 20 U of RNasin (Promega, Madison, WI)
and 10 mM DTT and this was stored at -80°C until
needed. Samples of the lysis buffer only were included as
a negative control for the RT-PCR and sample of lysis
buffer supplemented with total RNA extracted from
HNSCC cell line monolayers were used as a positive con-
trol for the RT-PCR. Samples were thawed on ice and the
RNA template denatured by incubation at 70°C for 3 min
before reverse transcription at 42°C using 3 μl pD(N)6
primers (Invitrogen), 200 μM each deoxyribonucleotide
triphosphate (dNTP) (Pharmacia, Uppsala, Sweden) and
200 U Superscript III reverse transcriptase (Invitrogen) in
Table 2: Primer pairs for amplification of marker gene sequences for RT-PCR expression and immunobead RT-PCR analyses.
Primer Name Primer Sequence
5'-3'
Annealing Temperature Product Size
ELF3 F CTCGGAGCTCCCACTCCTCAGA 68°C 188 bp
ELF3 R GCTCTTCTTGCCCTCGAGACAGT
EphB4 F CCCCAGGGAAGAAGGAGAGCTG 68°C 251 bp
EphB4 R GCCCACGAGCTGGATGACTGTG
EGFR F TGTGAGGTGGTCCTTGGGAATTTGG 66°C 339 bp
EGFR R TGCTGACTATGTCCCGCCACTGGA
CEA F GGTTGGGGTTGCTCTGATATAGCAGC 68°C 97 bp
CEA R GCTGTTGCAAATGCTTTAAGGAAGAAGC
CK19 F GACTACAGCCACTACTACACGACC 68°C 743 bp
CK19 R AGCCGCGACTTGATGTCCATGAGCC
EpCam F GGACCTGACAGTAAATGGGGAAC 68°C 186 bp
EpCam R CTCTTCTTTCTGGAAATAACCAGCAC
The sequences of forward (F) and reverse (R) primers for each of the markers are shown in 5' to 3' direction and were used at the indicated 
annealing temperature to generate a PCR product of the size indicated in base pairs (bp).Page 5 of 15
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sen marker genes was performed as before using 4 μl of
the resultant cDNA sample and 50 cycles of the amplifica-
tion reaction in a Corbett Rotor Gene 3000. Peripheral
blood samples from normal individuals and normal sam-
ples spiked with known numbers of tumour cell lines
were used as negative and positive controls, respectively.
Immunobead RT-PCR detection of circulating epithelial 
cells from patients with HNSCC
Two 10 ml samples of peripheral blood were collected
into EDTA tubes from an arterial line at the commence-
ment of surgery and another 2 samples were collected at
the end of surgery from the same source. The samples
were stored on ice and sent to the laboratory for process-
ing within the same day. The immunobead RT-PCR tech-
nique was performed as described above using the beads
commercially labelled with the BerEP4 antibody, CELLec-
tion Epithelial Enrich Dynabeads (Dynal, Invitrogen), to
ensure optimal isolation of circulating HNSCC expressing
the EpCam protein. Each patient sample was incubated
with 4 million beads on a low speed rotating wheel at 4°C
for between 1 and 4 h and then processed for RT-PCR
using the method described above.
Statistics
Statistical analysis and graphs were generated using
GraphPad Prism (v 4.0). Loco regional control and sur-
vival was analysed using the Kaplan-Meier method and
prognostic factors were assessed by Log-rank analysis.
Correlations between continuous variables were obtained
by linear regression analysis and Spearman's rank correla-
tion. Univariate analyses were performed and a Cox pro-
portional hazard model was used to analyse the effects of
patient, tumour and CTCs on disease specific survival, and
disease free survival. The following variables were consid-
ered in the Cox proportional hazard model - Age, Sex, T
stage, N stage and antigen expression. Two-tailed p-values
are given and considered statistically significant when p <
0.05.
Results
Comparison of attachment of immunobeads labelled with 
BerEP4 and EMA antibodies to HNSCC cell
Immunomagnetic enrichment of target cells relies on the
specific and efficient attachment of the beads to the target
cells. Immunomagnetic beads were coated with antibod-
ies targeting two different proteins reported to be present
on the surface of tumour cells of epithelial origin, BerEP4
which recognises the EpCam glycoprotein and EMA
which recognises the MUC1 protein. After 1 h incubation
in the conditions that would later be used to isolate CTCs
from patient samples, all cells and beads were collected
and attachment of the beads coated with the two different
antibodies to 4 different HNSCC cell line cells was deter-
mined using light microscopy (Figure 1). Beads coated
with the BerEP4 antibody were attached to 98 - 100% of
cells from all cell lines, and in most cases cells were heav-
ily rosetted with beads (Table 3). In contrast, beads coated
with the EMA antibody attached sparingly to 60% of cells
from the SCC-9, 51% of the FaDu cells, 30% of the SCC-
25 cells and only 14% of the Detroit cells (Table 3), with
only one or two beads attached in most cases. As beads
coated with the BerEP4 antibody attached in higher num-
bers to more cancer cells these were chosen for use in the
optimisation of HNSCC cell enrichment method.
Expression of markers in HNSCC cell lines
The expression of each of the chosen RT-PCR markers was
assessed in the representative HNSCC cell lines FaDu and
Detroit 562 to determine their suitability as markers for
use in the Immunobead RT-PCR assay. Total RNA was
Table 3: Comparison of the attachment of immunobeads coated with antibodies BerEP4 and EMA to cells from four HNSCC cell 
lines.
BerEP4 EMA
Cell line Cells with beads 
attached (%)
Average number of beads 
attached/cell
Cells with beads 
attached (%)
Average number of beads 
attached/cell
FaDu 100 ± 0 6.4 ± 3.1 51.0 ± 5.0 2.1 ± 1.3
Detroit 98 ± 2 7.0 ± 3.9 13.7 ± 4.2 1.4 ± 0.7
SCC-9 100 ± 0 10.0 ± 2.0 61.5 ± 2.5 2.4 ± 1.1
SCC-25 100 ± 0 13.0 ± 4.0 30.0 ± 2.0 1.4 ± 0.5
Cells were incubated with either BerEP4- or EMA-conjugated beads and a sample viewed using a light microscope. The BerEP4 antibody recognises 
the EpCam protein and the EMA antibody recognises Muc1/EMA/Mucin 1. The total number of cells and the number of these cells with beads 
attached were counted and the results are presented as a percentage of cells with beads attached. The average number of beads attached per cell 
was also determined.Page 6 of 15
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cDNA, then amplified using primers specific for each of
the different markers (Table 2). Transcripts corresponding
to EpCam were amplified in both of the cell lines, again
validating the use of antibodies that target this protein as
the antibody label for the magnetic isolation of the head
and neck carcinoma cells and confirming the immunoflu-
orescence result that showed bright staining in these lines
with the BerEP4 antibody (Figure 2, panel 2). EphB4,
EGFR and CK19 were amplified in both cell lines at con-
sistently high levels (Figure 2, panels 1, 3 and 6). ELF3/
ESX expression was also detectable in both cell lines (Fig-
ure 2, panel 5). CEA was only amplified from the Detroit
562 cell line and for this reason CEA was not chosen as a
marker in this study (Figure 2, panel 4).
Reconstruction "spiking" experiments to determine limit 
of detection of HNSCC cells in blood samples using 
immunobead-enrichment coupled with RT-PCR
To determine the limit of detection of HNSCC cells using
immunobead enrichment, known numbers of FaDu or
Detroit cells (10 to 500) were spiked into 10 ml normal
peripheral blood samples in triplicate and the immunob-
ead RT-PCR method was then used to re-isolate and iden-
tify them. Cells at the lowest dilution, equivalent to 1 cell
per ml of peripheral blood, were detected using the CK19
and Elf3/ESX markers although not in all samples indicat-
ing there may have been some loss of cells during the
immunobead isolation or that not all cells express these
markers at a sufficient level (Table 4). The lowest level of
detection of both cell lines using the EGFR and EphB4
markers was 5 cells per ml of peripheral blood. Alterna-
tively, failure to consistently detect expression of all mark-
ers in samples with low numbers of cells possibly reflects
heterogeneity of gene expression in the captured cells.
Immunobead RT-PCR analysis of blood samples from 
patients undergoing surgery for head and neck squamous 
cell carcinoma obtained prior to surgery
The expression of each of the 4 RT-PCR markers was
assessed in duplicate blood samples obtained prior to sur-
gery from 16 patients with head and neck cancers. Aliq-
uots of 500 cells from either the FaDu or Detroit HNSCC
cell lines, directly lysed in lysis buffer and reverse tran-
scribed concurrently with the patient samples, were used
as positive controls for each RT-PCR assay. As validated by
Brakenhoff et al (1999), patients were considered positive
for CTCs before surgery if the expression of at least two
markers was seen in at least one of the duplicate samples
(Table 5) [27]. Using this assay, 11 of the 16 cases ana-
lysed were positive for at least 2 markers (68.75%). Of the
positive cases, 1/11 (9%) showed expression of all 4
markers, 6 (54.5%) were positive for 3 markers, and 4
(36%) were positive for 2 markers. Importantly, two of
the patients in which CTCs were detected prior to surgery
had no other evidence of spreading disease (no perineural
invasion, vascular invasion or extracapsular spread).
Duplicate samples were analysed for agreement using a 2
tailed paired t-test. There was a significant correlation
between the samples taken pre-operatively for the antigen
ESX only, (p = 0.02).
Immunobead RT-PCR analysis of blood samples from 
patients undergoing surgery for head and neck squamous 
cell carcinoma obtained after surgery
The expression of each of the 4 RT-PCR markers was also
assessed in duplicate blood samples obtained after surgery
from the same cohort of patients. Patients were again con-
sidered positive if the expression of at least two markers in
at least one of the duplicate samples was detected after
Comparison of attachment of immunomagnetic beads conju-gated with either BerEP4 or EMA antibodies o h  and neck squamous cell carci ma cell li esFigure 1
Comparison of attachment of immunomagnetic 
beads conjugated with either BerEP4 or EMA anti-
bodies to head and neck squamous cell carcinoma 
cell lines. Detroit 562, FaDu, SCC-9 and SCC-15 cells were 
resuspended in phosphate buffered saline and incubated with 
labelled beads for 1 h before samples were viewed using a 
light microscope. The number of cells with beads attached 
and the number of beads attached per cell were counted by 
eye at 10× magnification.Page 7 of 15
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tive for at least 2 markers (62.5%). Of the positive cases,
3/10 (30%) showed expression of all 4 markers, 4 (40%)
were positive for 3 markers, and 3 (30%) were positive for
2 markers.
Expression of RT-PCR markers by stage
The expression of RT-PCR markers was evaluated against
clinical stage for all 16 patient samples of known stage.
Positive RT-PCR marker expression was detected before
surgery in 1/1 (100%) patients with Stage 1 disease, 4/6
(67%) patients with Stage 3 disease and 6/9 (67%)
patients with Stage 4a disease. Positive RT-PCR marker
expression was detected after surgery in 1/1(100%)
patients with Stage 1 disease, 5/6 (83%) patients with
Stage 3 disease and 4/9 (44%) patients with Stage 4a dis-
ease. Association of marker expression with stage was
tested using Fisher's exact test. The detection of dissemi-
nated disease using RT-PCR markers was not significantly
associated with tumour stage.
Expression of RT-PCR markers by tumour histology
Of the 16 patients, 2 were classified as well differentiated
tumours, 8 patients had moderately differentiated
tumours and 6 had poorly differentiated tumours. One of
the 2 patients with well differentiated tumours (50%), 6/
8 patients with moderately differentiated tumours (75%)
and 4/6 patients with poorly differentiated tumours
(67%) were positive for at least two markers before sur-
gery. Both of the 2 patients with well differentiated
tumours (100%), 4/8 patients with moderately differenti-
ated tumours (50%) and 4/6 patients with poorly differ-
entiated tumours (67%) were positive for at least two
markers after surgery.
Comparison of individual marker expression prior to and 
after surgery
There was marked variability in expression of each marker
in samples collected prior to and after surgery probably
reflecting likely genetic heterogeneity of the tumour cells
enriched from different individuals. Not all patients who
were positive before surgery were also positive after sur-
gery and vice versa. Furthermore often only one of the two
samples collected either prior to or after surgery was posi-
tive. The results are summarised in Table 5.
Comparison of patient outcome and marker expression, 
case-by-case
Four patients (Patients 6, 8, 11 and 16) had no evidence
of local recurrence or metastatic disease at the most recent
follow-up (22 - 33 months after surgery) even though
three of these patients were positive for at least 2 markers
prior to surgery and all four were positive for at least 2
markers after surgery. Only one patient (Patient 14) tested
negative for marker expression in all samples tested. This
patient did however have evidence of lymphovascular
invasion and local recurrence and later died with meta-
static disease.
Six other patients (Patients 2, 3, 4, 5, 13 and 15) had a
local recurrence of disease. For two of these patients
(Patients 2 and 5) the margins were involved after surgery
and there was evidence of either lymphovascular (Patient
2) or extracapsular spread (Patient 5) on pathological
examination. Both of these patients were also positive for
2 markers prior to their surgery but CTCs were not
detected in peripheral blood samples taken immediately
after. The other four patients with local recurrence were
also positive for at least two markers prior to surgery and
all remained positive after surgery. Three patients also all
had evidence of spread at the time of surgery, either
perineural (Patient 3), or extracapsular (Patients 4, 15).
Only one of these six patients was alive and disease free at
the last follow-up, a year after having had a second surgery
to remove the local recurrence (total laryngectomy).
Although pre- and post-operative blood samples were not
taken during this second surgical event, both duplicate
peripheral blood samples taken from this patient prior to
the first surgery were positive for EGFR, EphB4 and CK19
indicating that CTCs were already in the peripheral blood
of this patient.
Four patients (Patients 1, 7, 9 and 10) relapsed with met-
astatic disease at a distant site. Patients 7 and 9 were pos-
itive for at least two markers prior to surgery and remained
positive after surgery suggesting that the diseases in these
patients had already begun the metastatic process prior to
surgery. Both of these patients also had evidence of
spread, either extracapsular (Patient 7) or perineural
(Patient 9), as determined by pathological examination.
Patient 1 was positive for both ESX and CK19 in one of the
two peripheral blood samples taken after surgery. Simi-
larly, Patient 10 was negative for all markers prior to sur-
gery but was positive for EGFR, EphB4 and CK19 after.
Both patients were later diagnosed with distant metastases
and died from their diseases 33 and 19 months after the
initial surgery, respectively. This may suggest that tumor
cells were shed during surgical manipulation of the
tumour, however the surgical margin was involved with
tumour in both cases and there was evidence of extracap-
sular spread in Patient 10.
Patient 12 was not included in this analysis due to death
from causes unrelated to the disease or surgery.
Survival analysis
Kaplan-Meier survival analysis was performed using recur-
rence or death from disease as endpoints. The 3 year actu-
arial overall survival for the cohort was 37%, disease
specific survival was 40%, and disease free survival wasPage 8 of 15
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RT-PCR analysis of the expression of 6 markers in Detroit 562 and FaDu cellsFigure 2
RT-PCR analysis of the expression of 6 markers in Detroit 562 and FaDu cells. Total RNA from the Detroit 562 and 
FaDu cell lines was reverse transcribed then used in individual reactions to amplify products corresponding to each marker as 
indicated. cDNA from the breast cancer cell line MDA-MB-468 was used as a positive control for EphB4, EGFR, EpCam and 
Elf3. No RT = negative control for the reverse transcription reaction to which no enzyme was added, No RNA = negative con-
trol for the reverse transcription reaction to which no RNA was added, PCR -ve = PCR reagent only negative control. Marker 
= pUC19/HpaII. The size of the amplified product is shown in base pairs (bp). A genomic band is seen above the indicated RT-
PCR band for ELF3 and CEA.
BMC Cancer 2009, 9:424 http://www.biomedcentral.com/1471-2407/9/42427% (Figure 3). CTCs expressing each antigen from sam-
ples taken both pre- and post-operatively were compared
to overall survival, disease specific survival and disease
free survival but were not associated with significant dif-
ferences in survival or disease free survival in the cohort.
When considering the 6 patients (Patients 6, 7, 8, 11, 13
and 15) who were positive for the three markers, (ESX,
EGFR and EphB4) there was no significant correlation
with overall survival, p = 0.22).
Discussion
Despite significant advances in imaging, surgical manage-
ment and therapeutic options for the treatment of cancers
in general, there have been only modest improvement in
the outcomes for patients diagnosed with cancers of the
head and neck. The development of molecular marker-
based strategies have the potential to provide further
information that can contribute to the prognosis, treat-
ment selection and surveillance for recurrence and sec-
ondary tumour development [4]. In particular, the
identification of CTCs within peripheral blood samples
and bone marrow is an emerging area of research that may
facilitate the identification of tumours with the potential
of early metastasis [28].
Highly sensitive and specific techniques are required to
distinguish tumour cells from haematopoietic cells in
peripheral blood and bone marrow samples when they
are present in low concentrations, often as few as one to
five tumour cells per 10^6 to 10^7 haematopoietic cells
[4,26]. A variety of techniques have been employed to
identify these tumour cells including immunocytochem-
istry, typically using antibodies to detect cytokeratins, and
RT-PCR analysis using total RNA extracted from the nucle-
ated cell fraction in whole blood and lineage specific
markers [8,29-32]. More recently, methods for the posi-
tive or negative enrichment of tumour cells, prior to detec-
tion using PCR and RT-PCR assays, have reduced the rate
of false positivity from illegitimate expression of some
more commonly used markers in normal blood cells [33-
35].
In this study, the immunobead RT-PCR method, combin-
ing pre-analytical enrichment with magnetic beads coated
with the EpCam-specific BerEP4 antibody with RT-PCR
amplification of a panel of four markers, was optimised
for the detection of circulating HNSCC tumour cells in
peripheral blood samples. As it was considered unlikely
that normal epithelial cells would be present within the
peripheral blood [35,36], and malignant cells often con-
tinue to express markers that are characteristic of or spe-
cific for the normal tissue from which they originate [35],
we used a combination of markers that were either
expressed specifically in epithelial cells (Elf3/ESX and
CK19) [19-24] or have been reported to be over-expressed
in a high percentage of tumour cells from head and neck
origins (EGFR and EphB4) [14-18]. These markers were
also chosen for this study as they have already proven use-
ful in other immunobead RT-PCR studies using peripheral
blood samples from patients with breast and colon cancer
[10,11,37]. Reconstruction experiments using known
numbers of cells from two HNSCC cell lines, FaDu and
Table 4: Results of reconstruction experiments to optimise the 
immunobead RT-PCR method.
Marker Number of cells FaDu DETROIT
ESX 10 1 2
50 2 3
100 3 3
500 3 3
CK19 10 2 2
50 3 2
100 2 3
500 3 3
EGFR 10 0 0
50 3 2
100 2 2
500 3 2
EphB4 10 0 0
50 2 2
100 3 1
500 3 2
Frequency of detection of known numbers of FaDu and Detroit cells 
(Number of cells) inoculated into normal peripheral blood samples 
using the immunobead RT-PCR method with specific markers ESX, 
CK19, EGFR and EphB4. Triplicate samples were processed and the 
number of samples positive with each marker in the two different cell 
lines is indicated.Page 10 of 15
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BMC Cancer 2009, 9:424 http://www.biomedcentral.com/1471-2407/9/424Table 5: Results of Immunobead RT-PCR screening of peripheral blood samples from the 16 patients with head and neck cancers 
included in this study for marker expression.
Marker 1 Marker 2
ESX ESX ESX ESX EGFR EGFR EGFR EGFR
P# BF 1 BF 2 AF 1 AF 2 BF 1 BF 2 AF 1 AF 2
1 POS
2
3 POS
4 POS POS POS
5 POS
6 POS POS POS POS POS
7 POS POS POS POS POS POS
8 POS POS POS POS POS POS
9 POS POS POS
10 POS
11 POS POS POS POS POS
12 POS
13 POS POS POS POS
14
15 POS POS POS
16 POS
Marker 3 Marker 4
EphB4 EphB4 EphB4 EphB4 CK19 CK19 CK19 CK19
P# BF 1 BF 2 AF 1 AF 2 BF 1 BF 2 AF 1 AF 2
1 POS POS
2 POS POS POS
3 POS POS POS POS
4 POS POS
5 POS POS POSPage 11 of 15
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BMC Cancer 2009, 9:424 http://www.biomedcentral.com/1471-2407/9/424Detroit, inoculated into peripheral blood samples of nor-
mal individuals, were used to optimise the immunobead
RT-PCR method for the detection of head and cell cancer
cells and confirmed that this technique was able to con-
sistently identify the presence of tumour cells with the
required sensitivity of 1 to 5 cells per ml of peripheral
blood [4,26].
The immunobead RT-PCR assay was then used in a pilot
study to assess the long-term follow-up of 16 patients
with advanced stage HNSCC treated with primary surgical
resection and then with or without postoperative chemo-
therapy and/or radiotherapy. The 5-year actuarial disease
free and survival is in line with published data [38]. Not
surprisingly, given that all of the patients included in this
6 POS POS POS POS POS POS POS
7 POS POS POS POS POS POS
8 POS POS POS POS POS POS POS
9 POS POS POS POS POS POS
10 POS POS
11 POS POS POS
12 POS
13 POS POS POS POS POS POS
14
15 POS POS POS POS
16 POS POS POS
P# denotes patient number. Duplicate samples taken before surgery (BF) or after surgery (AF) were screened for expression of the four markers 
ESX, EGFR, EphB4 and CK19. Samples that were positive for individual markers are indicated (POS).
Table 5: Results of Immunobead RT-PCR screening of peripheral blood samples from the 16 patients with head and neck cancers 
included in this study for marker expression. (Continued)
Kaplan-Meier survival analysisFigure 3
Kaplan-Meier survival analysis. Comparison of survival data from patients positive or negative for epithelial cells in blood.Page 12 of 15
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evidence of disease spread at the time of surgery (Patient
9), 14/16 (87.5%) of the patients included in this study
did test positive for at least two of the chosen markers
either prior to or directly after surgery and are therefore
considered to have CTCs within their peripheral blood.
The presence of cells expressing these epithelial specific
and/or tumour-associated mRNAs at body sites where
these transcripts are not normally present, such as periph-
eral blood, implies that the tumours from these patients
have gained the capacity to spread through the vascular
system.
Marker positive cells were detected before surgery in two
patients, and after surgery in these two and a further two
patients who are alive and considered disease free as at the
most recent follow-up. Whilst the clinical significance of
CTCs in the peripheral blood of patients with HNSCC
remains unclear [4,28,39-41], this result would suggest
that the tumour cells in these patients have gained access
to the vascular circulation and they therefore have an
increased risk of relapse and should be carefully moni-
tored for potential recurrence/relapse. In this study three
patients, who were not positive for CTCs prior to surgery,
tested positive for CTCs after surgery. This may indicate
that surgical manipulation of the primary tumours in
these individuals has resulted in dissemination of tumour
cells into the circulation but the clinical relevance of cells
disseminated by surgery is a subject of debate.
Only one patient (Patient 14) was not identified as having
CTCs either before or after surgery. This patient did how-
ever have evidence of lymphovascular invasion and later
died from a locoregional recurrence and metastatic dis-
ease. It is well recognised that CTCs are not always
detected even when advanced metastatic disease is present
and this is presumed to be the result of either sampling
errors [42], intermittent tumor cell shedding [43], effec-
tive immune surveillance [44] or stochastic effects at the
lower limits of sensitivity of the assay [45]. In addition, it
cannot be assumed that the assay used in this study was
able to detect all CTCs with uniform sensitivity even
though a panel of four different markers was used, partic-
ularly if the tumour cells from this patient did not actually
express these markers. Possible improvements might be
gained through the inclusion of further markers to ensure
the identification of all CTCs. Promising markers for head
and neck cancers include parathyroid hormone-like hor-
mone (PTHLH, also known as PTHrP), serpin peptidase
inhibitor, clade B (ovalbumin), member 3 (SERPINB, also
known as SCCA), and lymphocyte antigen 6 complex,
locus D (LY6D, also known as E48) [8,29,30].
Ten patients included in this study had CTCs positive for
EGFR. EGFR is commonly up-regulated in head and neck
cancers and this receptor has emerged as a key molecular
target for anti-cancer therapies including the monoclonal
antibody therapy Cetuximab licensed for the treatment of
HNSCC [46]. The immunobead RT-PCR method, devel-
oped here for detecting CTCs expressing EGFR, may pro-
vide an important future clinical application for
monitoring the efficacy of systemic therapies through the
real-time monitoring of EGFR-positive CTCs in cancer
patients during their treatment.
Detection of disseminated cells can identify patients who
may develop distant metastases and therefore have
reduced survival. A recent study comparing immunocyto-
chemistry with a pan-cytokeratin antibody and RT-PCR
for LY-6/E48 expression for detection of disseminated
cells in bone marrow and blood from 40 patients with
HNSCC, showed that detection of cells in pre-operative
bone marrow and blood correlated with the development
of both locoregional recurrence and distant metastasis
[30]. In the study reported here however, there was no
association between the detection of CTCs and any signif-
icant reduction in progression free survival or overall sur-
vival. This may be due to both the small number of
patients included in this pilot study and the fact that
nearly all of them were diagnosed with advanced disease,
which is associated with poor prognosis.
Conclusion
An immunobead RT-PCR method, combining immu-
nomagnetic enrichment of tumor epithelial cells with RT-
PCR analysis of ESX, EGFR, EphB4 and CK19 was opti-
mised using reconstruction experiments with two HNSCC
cell lines, then used to detect CTCs in the peripheral blood
from 16 patients with advanced HNSCC. Samples from
fourteen of these patients were positive for at least two of
the chosen markers and were therefore considered posi-
tive for CTCs. This is the first study to report that, at the
time of surgery, circulating cells can be detected in the
peripheral blood of almost all patients with advanced
head and neck cancers. This result demonstrates the clini-
cal utility of immunobead RT-PCR as a minimally inva-
sive technique that facilitates the rapid screening of
patient peripheral blood for CTCs associated with head
and neck cancers, and therefore the potential for develop-
ing this assay for future incorporation into the clinical set-
ting. Techniques that accurately detect CTCs will find
utility for detection of spreading disease, routine monitor-
ing of disease progression and for determining the efficacy
of adjuvant systemic treatments.
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